ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) today announced that it has been accepted as an associate member of the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI) focused on the development of molecular technologies for the screening, early diagnosis and target-based treatment of cancer.
